TVI-Brain-1
Glioblastoma (Brain Cancer)
Phase 2bActive
Key Facts
About TVAX Biomedical
TVAX Biomedical is a private, clinical-stage biotech focused on a novel, two-step personalized immunotherapy platform designed to treat a broad range of cancers with low toxicity. Its lead candidate, TVI-Brain-1, is in a pivotal Phase 2b trial for glioblastoma, supported by FDA Fast Track and Orphan Drug designations. The company leverages over 50 years of foundational research to create patient-specific therapies that aim to train the immune system to recognize and attack a patient's unique tumor antigens. Management combines deep scientific expertise in immunology with pharmaceutical development and operational experience.
View full company profileTherapeutic Areas
Other Glioblastoma (Brain Cancer) Drugs
| Drug | Company | Phase |
|---|---|---|
| SI-053 | Double Bond Pharmaceutical | Pre-clinical |